Business
Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019
SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially
About this update from Immunic, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Andreas Muehler, M.D., Chief Medical Officer of Immunic, will present today selected available and previously unpublished preclinical data summarizing the profile of its lead oral compound, IMU-838, as compared to the dihydroorotate dehydrogenase (DHODH) inhibitor, teriflunomide, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019 in Stockholm, Sweden. The poster will be presented during Poster Session 1 being held today, from 5:15 pm to 7:15 pm CEST. IMU-838, in phase 2 development for relapsing-remitting multiple sclerosis (RRMS) and ulcerative colitis, is a novel, orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking DHODH.\nThe poster, entitled, \"The DHODH Inhibitor IMU-838/Vidofludimus Calcium Shows a Superior Compound Profile as Compared to the Approved DHODH Inhibitor, Teriflunomide,\" co-authored by Dr. Muehler, Hella Kohlof, Ph.D., Chief Scientific Officer of Immunic, Manfred Gröppel, Ph.D., Chief Operating Officer of Immunic and Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, highlights the favorable profile of IMU-838 regarding safety, biological selectivity, pharmacokinetics and potency, as compared to teriflunomide. Highlights of Dr. Muehler's presentation will include these selected and previously unpublished findings:\nSelectivity for DHODH, and IMU-838's lack of off-target effects on kinases were confirmed; IMU-838 showed a strong cytokine inhibition on stimulated human peripheral blood lymphocytes; IMU-838's short blood half-life of approximately 30 hours should make it favorable for once-daily dosing, as well as rapid wash-out, if needed; Treatment with IMU-838 results in fast onset, reaching steady state concentrations within 5 to 7 days; Dosing in humans did not result in increased rates of diarrhea, alopecia or neutropenia, as compared to placebo; Due to biological selectivity, the molecule has no general antiproliferative effect on immune cells.\"These previously unpublished data, which we...